stockrow
Saturday 7 November 2026
Export SER’s income statement to Excel — free account
Serina Therapeutics, Inc.
Serina Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $130,000.00, up 132.1% from fiscal 2024.
- Revenue
- +2,500.0%
- EPS
- +16.7%
- Free cash flow
- −76.8%
Quarter to June 2026, against a year earlier
1.40
0.25
−15.15%
Follow SER
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
6.12 | 3.87 | 0.86 | 0.98 | |
Current Ratio |
6.65 | 4.18 | 1.71 | 1.31 | |
Net Debt/EBITDA |
2.98 | 3.47 | 0.02 | 0.90 | |
Debt/Assets |
11.96% | 11.03% | 42.38% | 23.27% | |
Debt/Equity |
0.16 | 0.17 | (79.62) | 1.81 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.75 | 0.66 | 1.87 | 0.84 | |
Capex/Depreciation |
(0.29) | (0.30) | 0.00 | (0.81) | |
Interest Coverage |
(33.42) | (33.23) | (31.35) | (1,065.33) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.41) | (0.38) | (0.59) | (0.37) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.41) | (0.38) | (0.59) | (0.37) | |
Cash per Share |
1.41 | 2.04 | 0.30 | 0.83 | |
Shareholders Equity per Share |
1.14 | 1.46 | 0.00 | 0.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.14 | 1.46 | 0.00 | 0.15 | |
Free Cash Flow |
(6.71) | (4.59) | (6.03) | (3.86) | |
Working Capital |
21.27 | 20.13 | 2.52 | 2.71 | |
Capital Expenditures |
(0.03) | (0.02) | 0.00 | (0.01) | |
Net Current Asset Value |
17.95 | 16.80 | (0.91) | 0.68 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.78 | 2.01 | 1.34 | 2.21 | |
Average Assets |
17.38 | 17.02 | 6.84 | 9.92 | |
Average Common Equity |
7.72 | 7.12 | (2.23) | (8.59) |
Columns are period end dates · fundamentals updated 25 Oct 2026